Overview

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1 study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer(NSCLC).

Phase:

Phase 1

Details

Lead Sponsor:

Vitrac Therapeutics, LLC

Collaborator:

Westat